Results 191 to 200 of about 23,539 (262)

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Estimating personal temporal symptom networks for childhood cancer survivors. [PDF]

Commun Med (Lond)
Zhou Y, Deshpande S, Horan MR, Choi J, Mulrooney DA, Ness KK, Hudson MM, Srivastava DK, Huang IC.   +8 more
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation. [PDF]

J Clin Oncol
Yeh JM, Seguin CL, Stratton KL, Leisenring WM, Armstrong GT, Henderson TO, Henderson TO, Hudson MM, Nathan PC, Neglia JP, Oeffinger KC, Diller LR, Knudsen AB.   +12 more
europepmc   +1 more source

Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy

British Journal of Clinical Pharmacology, EarlyView.
Aims Vincristine‐induced peripheral neuropathy (VIPN) is a common side effect in children and adolescents treated with vincristine. Assessing VIPN, especially in young children, is challenging due to a lack of sensitive tools. This limits our understanding of the nature and risk factors of VIPN. This study aimed to investigate neurofilament light chain
Peter Erik Lotko Pontoppidan, Christian Bach Vase, Christina Mortensen, Liv Andres‐Jensen, Dorte Aalund Olsen, Jonna Skov Madsen, Kjeld Schmiegelow, Rene Mathiasen, Tore Bjerregaard Stage   +8 more
wiley   +1 more source

Stressful Events Reported by Childhood Cancer Survivors and Community Controls From the St. Jude Lifetime (SJLIFE) Cohort: A Mixed Method Study. [PDF]

Pediatr Blood Cancer
Ware ME, Clayton CK, Wang F, Mirzaei S, Shelton K, Brinkman TM, Willard V, Sharp KMH, Krull K, Schwartz LF, Hudson MM, Armstrong GT, Ness KK, Webster RT.   +13 more
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Radiomorphometric indices and bone findings on panoramic images of childhood cancer survivors. [PDF]

Imaging Sci Dent
Barros AMI, Sobral APV, de Azevedo LPM, Rodrigues CD, de Almeida HCR, da Silveira MMF.   +5 more
europepmc   +1 more source

Barriers to Care for Childhood Cancer Survivors at Risk for Late Cardiovascular Disease: A Mixed Methods Approach. [PDF]

Cancer Surviv Res Care
Noyd DH, Anderson-Buettner A, Bouvette S, Bailey A, Janitz A, Chen S, Nagykaldi Z.   +6 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source